ASTRAZEN - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.2
| Stock Code | ASTRAZEN | Market Cap | 20,896 Cr. | Current Price | 8,370 ₹ | High / Low | 10,691 ₹ |
| Stock P/E | 100 | Book Value | 320 ₹ | Dividend Yield | 0.38 % | ROCE | 33.4 % |
| ROE | 23.6 % | Face Value | 2.00 ₹ | DMA 50 | 8,693 ₹ | DMA 200 | 8,660 ₹ |
| Chg in FII Hold | -0.03 % | Chg in DII Hold | 0.29 % | PAT Qtr | 31.6 Cr. | PAT Prev Qtr | 58.1 Cr. |
| RSI | 36.9 | MACD | -82.7 | Volume | 3,355 | Avg Vol 1Wk | 5,632 |
| Low price | 6,502 ₹ | High price | 10,691 ₹ | PEG Ratio | 2.32 | Debt to equity | 0.04 |
| 52w Index | 44.6 % | Qtr Profit Var | -42.3 % | EPS | 80.4 ₹ | Industry PE | 27.2 |
📊 Based on the given parameters, AstraZeneca (ASTRAZEN) shows strong fundamentals in terms of ROCE (33.4%) and ROE (23.6%), which indicate efficient capital usage and profitability. However, the stock trades at a very high P/E of 100 compared to the industry average of 27.2, suggesting overvaluation. The PEG ratio of 2.32 also indicates limited growth potential relative to its valuation. Dividend yield is modest at 0.38%, making it less attractive for income-focused investors.
💡 Entry Price Zone: Considering the RSI (36.9, near oversold), MACD (-82.7, bearish), and support levels around 6,500–7,200 ₹, the ideal entry zone would be closer to 6,800–7,200 ₹ for long-term investors.
📈 Exit Strategy / Holding Period: If already holding, investors should maintain a long-term horizon (3–5 years) given the strong ROE/ROCE and low debt-to-equity (0.04). However, monitor quarterly profit trends (currently down 42.3%) and consider partial profit booking if the price revisits 10,000–10,500 ₹ levels. Long-term holding is justified if earnings growth stabilizes and valuation moderates.
Positive
- Strong ROCE (33.4%) and ROE (23.6%) indicate efficient capital use.
- Low debt-to-equity ratio (0.04) ensures financial stability.
- Global pharmaceutical presence with diversified product portfolio.
Limitation
- High P/E (100) compared to industry average (27.2).
- PEG ratio (2.32) suggests overvaluation relative to growth.
- Dividend yield (0.38%) is low for income investors.
Company Negative News
- Quarterly profit dropped by 42.3% (PAT down from 58.1 Cr. to 31.6 Cr.).
- FII holding slightly reduced (-0.03%).
Company Positive News
- DII holdings increased (+0.29%), showing domestic institutional confidence.
- Strong long-term fundamentals with consistent ROCE and ROE.
Industry
- Pharma industry P/E average: 27.2, indicating AstraZeneca trades at a premium.
- Sector growth driven by innovation, global demand, and healthcare expansion.
Conclusion
⚖️ AstraZeneca is fundamentally strong but currently overvalued. Long-term investors should wait for a correction toward 6,800–7,200 ₹ before entering. Existing holders can maintain positions with a 3–5 year horizon, but should monitor earnings growth and consider partial exits near 10,000 ₹ levels. The stock is a cautious long-term hold rather than an aggressive buy at current valuations.